Cancer Victim: Monsanto Is Liable Due To 'Wrongful Conduct' Regarding Glyphosate
MINNEAPOLIS - A cancer victim on Aug. 14 sued Monsanto Co. in Minnesota federal court, contending that exposure to glyphosate, the active ingredient in the company's herbicide Roundup, caused his T-cell lymphoma and that Monsanto is liable for "negligent and wrongful conduct" associated with the manufacture and distribution of the chemical (Clifford McCord v. Monsanto Company, No. 19-2252, D. Minn.). (Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News)
Source: LexisNexis® Mealey's™ Emerging Toxic Torts Legal News - August 21, 2019 Category: Medical Law Source Type: news

British women who developed a form of cancer linked to their breast implants launch legal action
Linzy Bromfield, 50, (pictured) 'thought she was going to die' after she developed implant-associated lymphoma in 2016. She had the implants put in at a private clinic in the UK in 2005. (Source: the Mail online | Health)
Source: the Mail online | Health - August 16, 2019 Category: Consumer Health News Source Type: news

Women's Wellness: Recall for textured breast implants and tissue expanders
Allergen textured breast implants and tissue expanders are being removed from the U.S. market, due to the risk of breast implant-associated anaplastic large cell lymphoma. That's according to a recent statement from the maker and the Food and Drug Administration (FDA). "BIOCELL?saline-filled and silicone-filled textured breast implants and tissue expanders will no longer be distributed [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - August 15, 2019 Category: Databases & Libraries Source Type: news

Nanocapsule reaches cancer that has spread to central nervous system in mice
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small ...
Source: UCLA Newsroom: Health Sciences - August 14, 2019 Category: Universities & Medical Training Source Type: news

Clinical Trial Offering Personalized Immunotherapy for Mesothelioma
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still ha...
Source: Asbestos and Mesothelioma News - August 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

UAMS Cancer Researcher Awarded $542K Grant
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that affects the development and advancement of multiple myeloma. (Source: Arkansas Business - Health Care)
Source: Arkansas Business - Health Care - August 13, 2019 Category: American Health Source Type: news

Early Progression of Advanced Follicular Lymphoma with Poor Outcomes Linked to New Combo
While many patients with follicular lymphoma did well with this new regimen, the majority of those who did have disease progression had transformed disease. (Source: CancerNetwork)
Source: CancerNetwork - August 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Examining MRD-Driven Consolidation with Rituximab in Early Stage Follicular Lymphoma
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given  rituximab to see how it affected progression-free survival.  (Source: CancerNetwork)
Source: CancerNetwork - August 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Medicare to Cover CAR-T Therapy for Leukemia, Lymphoma
THURSDAY, Aug. 8, 2019 -- A breakthrough gene therapy will be covered for certain types of lymphoma and leukemia, Medicare says. Chimeric antigen receptor T-cell (CAR-T) therapy boosts a patient's own immune cells to fight cancer and can cost... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 8, 2019 Category: Pharmaceuticals Source Type: news

Health Highlights: Aug. 8, 2019
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Medicare to Cover Breakthrough Gene Therapy for Leukemia, Lymphoma A breakthrough gene therapy will be covered for certain types of lymphoma... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 8, 2019 Category: General Medicine Source Type: news

Medicare to Cover Breakthrough Gene Therapy for Leukemia, Lymphoma
Title: Medicare to Cover Breakthrough Gene Therapy for Leukemia, LymphomaCategory: Health NewsCreated: 8/8/2019 12:00:00 AMLast Editorial Review: 8/8/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 8, 2019 Category: Cancer & Oncology Source Type: news

Should Patients with DLBCL and Concurrent FL be Included in Clinical Trials?
Researchers from the Mayo Clinic in Rochester, Minn. examined the disease histology   and outcomes of patients with diffuse large B-cell lymphoma and a concurrent lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Woman, 27, has shared her 10 top tips on how to smile through chemotherapy 
Georgie Swallow, of Buckinghamshire thought she had eczema for a year before her diagnosis of Hodgkin lymphoma in September 2018. But she remains optimistic. (Source: the Mail online | Health)
Source: the Mail online | Health - August 7, 2019 Category: Consumer Health News Source Type: news

Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with  relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Translator was diagnosed with stage-four cancer after she dismissed her cough as 'part of winter' 
Magdalena Bujalski, 22, of Winnipeg, Canada, was told her cough was likely just bronchitis, until an X-ray revealed an unusual mass on her right lung. She was diagnosed with Non-Hodgkin Lymphoma. (Source: the Mail online | Health)
Source: the Mail online | Health - August 5, 2019 Category: Consumer Health News Source Type: news

Routine PET field-of-view enough for pediatric lymphoma
A routine "eyes to thighs" field-of-view with FDG-PET/CT scans is more than...Read more on AuntMinnie.comRelated Reading: Top 5 clinical applications of pediatric 3D printing SNMMI: Whole-body dynamic PET matches standard images SNMMI: PET spotlights link between Down syndrome, Alzheimer's NaF-PET/CT rarely finds prostate cancer metastases PET/MRI matches PET/CT with less radiation for children (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 5, 2019 Category: Radiology Source Type: news

Merril Hoge opens up about the cancer he believes was caused by Roundup
A former NFL player is joining thousands of people suing the company behind Roundup, a popular weed killer with a chemical linked to cancer. In a lawsuit made public Wednesday, 54-year-old Merril Hoge says he developed non-Hodgkin ’s lymphoma as a direct result of being exposed to the herbicide. Meg Oliver reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 1, 2019 Category: Consumer Health News Source Type: news

Former football player sues Roundup weedkiller maker
Former Pittsburgh Steelers running back Merril Hoge is among the thousands of plaintiffs suing Roundup maker Monsanto alleging his exposure to its weed killer caused him to develop non-Hodgkins lymphoma. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - August 1, 2019 Category: Consumer Health News Source Type: news

Expensive Gilead, Novartis cancer therapies losing patients to experimental treatments
Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG , new data shows, helping explain why sales of the two products have not met rosy expectations. (Source: Reuters: Health)
Source: Reuters: Health - July 31, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Celebrating simple moments after individualized cancer therapy
Making long-term plans was not always part of Tanis Milicevic's daily routine. Milicevic was diagnosed with non-Hodgkin lymphoma more than a decade ago. But the past year has been markedly different for the Ponte Vedra Beach, Florida, resident. June 14 was her one-year anniversary as Florida's first successful chimeric antigen receptor therapy (CAR-T cell therapy) [...] (Source: Mayo Clinic Florida News)
Source: Mayo Clinic Florida News - July 31, 2019 Category: Hospital Management Source Type: news

Clinical Trials Bite Off Chunk of CAR T Therapy Market
About a quarter of lymphoma patients eligible for the cancer treatments are opting for experimental--and free--options instead. (Source: The Scientist)
Source: The Scientist - July 30, 2019 Category: Science Tags: News & Opinion Source Type: news

Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental Treatments Expensive Gilead, Novartis Cancer Therapies Losing Patients to Experimental Treatments
Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG, new data shows, helping explain why sales of the two products have not met rosy expectations.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Gilead, Novartis cancer therapies losing patients to experimental treatments
Unusually high numbers of U.S. lymphoma patients are choosing experimental treatments over expensive cell therapies sold by Gilead Sciences Inc and Novartis AG , new data shows, helping explain why sales of the two products have not met rosy expectations. (Source: Reuters: Health)
Source: Reuters: Health - July 30, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

HCV Infection and Non-Hepatic Malignancies in the DAA Era HCV Infection and Non-Hepatic Malignancies in the DAA Era
What are the effects of HCV viral eradication on non-hepatic cancers? This review focused on the impact of DAA therapy on non-Hodgkins'lymphoma and extrahepatic solid tumors.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Mantle Cell Lymphoma With Mantle Zone Growth Pattern Mantle Cell Lymphoma With Mantle Zone Growth Pattern
This study aimed to characterize the clinical, morphologic, and immunophenotypic features of mantle cell lymphoma with mantle zone growth pattern.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 30, 2019 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Trump Signs 9/11 Victims Fund Extension
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - July 29, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Bayer extends winning streak, with $2B Roundup verdict reduced to $86.7M
The more than $2 billion verdict against Bayer and its Roundup weed killer has been reduced to $86.7 million by a judge in Oakland, California. A jury in the case in May had awarded more than $2 billion in damages to a husband and wife who contended their use of Roundup caused their non-Hodgkin's lymphoma. Bayer called the ruling Thursday “a step in the right direction,” but said it plans to appeal because “we continue to believe t hat the verdict and damage awards are not supported by the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 26, 2019 Category: Pharmaceuticals Authors: Greg Edwards Source Type: news

Pediatric Lymphoma Joins Family of BRCA2 Cancers Pediatric Lymphoma Joins Family of BRCA2 Cancers
Researchers call for genetic testing of all survivors of pediatric non-Hodgkin lymphoma after data revealed BRCA2 is implicated in the childhood disease.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The BRCA2 gene also raises the risk of childhood non-Hodgkin's lymphoma, study finds 
A new study from St Jude Children's Research Hospital has found that about two percent of childhood survivors of non-Hodgkin's lymphoma had inherited mutation of the BRCA2 gene. (Source: the Mail online | Health)
Source: the Mail online | Health - July 25, 2019 Category: Consumer Health News Source Type: news

ASCT May Offer Alternative for Tx of High - Risk Follicular Lymphoma
Autologous stem cell transplantation explored for high - risk, early therapy failure FL prior to rituximab use (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 25, 2019 Category: Cancer & Oncology Tags: Oncology, Institutional, Source Type: news

Textured breast implant recipient on cancer diagnosis: It was "total shock"
A major producer of breast implants is stopping the sale and distribution of their textured products, amid growing links to a rare and deadly cancer. The FDA requested the recall from Allergan after a "significant increase" in cases of a particular lymphoma. The FDA says the risk of lymphoma with Allergan's Biocell textured implants is approximately six times that of other manufacturers who are marketing in the U.S. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 25, 2019 Category: Consumer Health News Source Type: news

Major breast implant producer issues recall after growing cancer concerns
A major producer of breast implants is stopping the sale and distribution of their textured products, amid growing links to a rare and deadly cancer. The FDA requested the recall from Allergan after a "significant increase" in cases of a particular lymphoma. The FDA says the risk of lymphoma with Allergan's Biocell textured implants is approximately six times that of other manufacturers who are marketing in the U.S. Anna Werner reports. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 25, 2019 Category: Consumer Health News Source Type: news

ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma
THURSDAY, July 25, 2019 -- Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, according to a study published online July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 25, 2019 Category: Pharmaceuticals Source Type: news

Antibiotics can inhibit skin lymphoma
(University of Copenhagen The Faculty of Health and Medical Sciences) New research from the LEO Foundation Skin Immunology Research Center at the University of Copenhagen shows, surprisingly, that antibiotics inhibit cancer in the skin in patients with rare type of lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 25, 2019 Category: International Medicine & Public Health Source Type: news

Textured Breast Implants Recalled for Cancer Risk
The FDA says the textured surface, unique to Allergan’s implants, are tied to 481 cases of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a type of non-Hodgkin’s lymphoma. (Source: WebMD Health)
Source: WebMD Health - July 25, 2019 Category: Consumer Health News Source Type: news

FDA Asks Allergan to Recall Textured Breast Implants
FDA has finally drawn a line in the sand on an issue that has plagued the breast implant industry for years. On Wednesday the U.S. regulatory agency called on Allergan to take specific models of its textured breast implants off the market due to the risk of a rare type of cancer. "To protect individuals from the increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) associated with Allergan Biocell textured breast implants, [FDA] requested that Allergan recall its Biocell textured breast implants and tissue expanders," the agency said in a safety communicatio...
Source: MDDI - July 24, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Regulatory and Compliance Source Type: news

Allergan Recalls Textured Breast Implants Linked to Lymphoma
WEDNESDAY, July 24, 2019 -- Allergan's textured breast implants will be recalled due to their link to a rare cancer, the U.S. Food and Drug Administration announced Wednesday. Following a request from the FDA, the company will proceed with a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2019 Category: Pharmaceuticals Source Type: news

Popular breast implant recalled worldwide after more evidence of a link to rare cancer
The implants, which have a textured surface to prevent slipping, have long been linked to a cancer of the immune system called BIA-ALCL (breast-implant associated anaplastic large cell lymphoma). (Source: the Mail online | Health)
Source: the Mail online | Health - July 24, 2019 Category: Consumer Health News Source Type: news

Cancer Risks Examined in Rheumatoid Arthritis Patients
Increased incidences found for lymphoma, lung cancer (in male patients), and cervical cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 24, 2019 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Internal Medicine, Oncology, Pulmonology, Rheumatology, Journal, Source Type: news

Allergan Pulls Textured Breast Implants in US and Worldwide Allergan Pulls Textured Breast Implants in US and Worldwide
The recall comes after an increase in reports of breast implant-associated anaplastic large cell lymphoma; the FDA says 573 unique cases and 33 deaths have been reported worldwide.News Alerts (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Textured Breast Implants Recalled Because of Link to Rare Cancer
(WASHINGTON) — Breast implant maker Allergan Inc. issued a worldwide recall Wednesday for textured models because of a link to a rare form of cancer. The U.S. Food and Drug Administration said it called for the removal after new information showed Allergan’s Biocell breast implants with a textured surface account for a disproportionate share of rare lymphoma cases. The move follows similar action in France, Australia and Canada. The FDA is not recommending women with the implants have them removed if they are not experiencing problems. Biocell implants feature a textured surface designed to prevent slippage and...
Source: TIME: Health - July 24, 2019 Category: Consumer Health News Authors: MATTHEW PERRONE / AP Tags: Uncategorized Cancer onetime Source Type: news

Breast Implants Linked to Rare Cancer Are Recalled Worldwide
Under pressure from the Food and Drug Administration, Allergan will stop selling textured implants. 33 deaths have been tied to this type of implant. (Source: NYT)
Source: NYT - July 24, 2019 Category: American Health Authors: Denise Grady Tags: Allergan Inc Cancer Breasts Implants Non-Hodgkin ' s Lymphoma Recalls and Bans of Products Food and Drug Administration your-feed-healthcare Source Type: news

Allergan recalls textured breast implants linked to rare cancer
More than 500 cases of implant-associated lymphoma have been linked to textured implants worldwide, and most of the implicated devices were made by Allergan, the FDA said. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - July 24, 2019 Category: Consumer Health News Authors: Laurie McGinley Source Type: news

FDA Takes Action to Protect Patients from Risk of Certain Textured Breast Implants; Requests Allergan Voluntarily Recall Certain Breast Implants and Tissue Expanders from Market
SILVER SPRING, Md., July 24, 2019 -- (Healthcare Sales & Marketing Network) -- The U.S. Food and Drug Administration today took significant action to protect women from breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) by requesting that... Devices, FDA, Product Recall Allergan, BIOCELL, Textured Breast Implant, Tissue Expander (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 24, 2019 Category: Pharmaceuticals Source Type: news

Senate Passes 9/11 Victim Compensation Fund Extension
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

9/11 Victims Fund Passes Senate
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092. The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092. The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers unveil experimental compound to block therapeutic target in blood cancer
(UNC Lineberger Comprehensive Cancer Center) UNC Lineberger Comprehensive Cancer Center researchers have discovered a hyperactive cell signal that contributes to tumor growth in primary effusion lymphoma, an aggressive type of non-Hodgkin lymphoma caused by infection with the Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8). They also reported in the PNAS paper that they've developed an experimental therapeutic, UNC3810A, to block the signal and slow tumor growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2019 Category: Cancer & Oncology Source Type: news

Steelers' James Conner reveals he was told he'd die after cancer diagnosis if he didn't get treated
Pittsburgh Steelers running back James Conner, 24, was diagnosed with stage 2 Hodgkin's lymphoma in 2015. After six months of chemotherapy, he was declared cancer-free. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2019 Category: Consumer Health News Source Type: news

Cancer sufferer was diagnosed with advanced tumours after sipping on wine triggered painful itching
Lauren Firenza, 25, of Nottingham, noticed a tingling sensation while at a family get together in December last year. She was diagnosed with stage four Hodgkin lymphoma in April. (Source: the Mail online | Health)
Source: the Mail online | Health - July 18, 2019 Category: Consumer Health News Source Type: news